KROS Q2 2025 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+49002.7% YoY

Gross Profit

$18M98.0% margin

Operating Income

-$40M-219.2% margin

Net Income

-$31M-169.0% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

-91.4%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$757M

Total Liabilities

$50M

Stockholders' Equity

$707M

Cash & Equivalents

$690M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$37,000	+49002.7%
Gross Profit	$18M	$37,000	+48002.7%
Operating Income	-$40M	-$50M	+21.1%
Net Income	-$31M	-$45M	+32.2%

Revenue Segments

Service, Other

$18M100%